---
title: "Barclays Keeps Their Buy Rating on AnaptysBio (ANAB)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292599229.md"
description: "Barclays analyst Etzer Darout maintained a Buy rating on AnaptysBio (ANAB) with a $75 price target. TipRanks also launched the RANK ETF, tracking its US Momentum Analysts Index. Darout holds a 5-star status with a 30.7% average return. The broader market consensus for AnaptysBio is Strong Buy, with an average price target of $80.67."
datetime: "2026-07-14T08:46:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292599229.md)
  - [en](https://longbridge.com/en/news/292599229.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292599229.md)
generator: "portal-rs"
---

# Barclays Keeps Their Buy Rating on AnaptysBio (ANAB)

In a report released today, Etzer Darout from Barclays maintained a Buy rating on AnaptysBio, with a price target of $75.00.

### TipRanks Welcomes a New ETF – NYSE:RANK

-   TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
-   RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

According to TipRanks, Darout is a 5-star analyst with an average return of 30.7% and a 63.35% success rate. Darout covers the Healthcare sector, focusing on stocks such as Incyte, Legend Biotech, and Abivax SA Sponsored ADR.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for AnaptysBio with a $80.67 average price target.

### Related Stocks

- [ANAB.US](https://longbridge.com/en/quote/ANAB.US.md)
- [RANK.US](https://longbridge.com/en/quote/RANK.US.md)
- [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md)
- [BCS.US](https://longbridge.com/en/quote/BCS.US.md)
- [INCY.US](https://longbridge.com/en/quote/INCY.US.md)
- [LEGN.US](https://longbridge.com/en/quote/LEGN.US.md)
- [ABVX.US](https://longbridge.com/en/quote/ABVX.US.md)

## Related News & Research

- [ANAB: Jemperli sales surged 34% year-over-year, fueling strong earnings and positive regulatory momentum](https://longbridge.com/en/news/299680376.md)
- [AnaptysBio GAAP EPS of $5.11 beats by $5.02, revenue of $27.5M beats by $7.38M](https://longbridge.com/en/news/299680696.md)
- [AnaptysBio (ANAB) Gets a Buy from Leerink Partners](https://longbridge.com/en/news/299613459.md)
- [AnaptysBio Q2 FY26 net income from continuing operations more than doubles to $177.3 million; revenue rises 23.5% to $27.49 million](https://longbridge.com/en/news/299679757.md)
- [Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update | ANAB Stock News](https://longbridge.com/en/news/286154975.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**